期刊文献+

反应停对人类肺腺癌细胞系血管内皮生长因子表达影响 被引量:4

Effect of Thalidomide on the Expressions of Vascular Endothelial Growth Factor in Human Lung Adenocarcinoma Cell Line
下载PDF
导出
摘要 目的 :探讨反应停对亲代与耐顺铂人类肺腺癌细胞系A549 与A549 血管内皮生长因子 (VEGF)表达的影响 ,及在克服肺腺癌顺铂耐药中的作用。方法 :采用RT_PCR和免疫细胞化学方法 ,分别检测经反应停处理前后A549 与A549 VEGFmRNA与蛋白的表达水平。结果 :生理剂量 (6mg/L)反应停处理后第1~5d ,A549 VEGFmRNA表达较处理前显著增加 ,A549 VEGFmRNA表达较处理前显著降低。不同浓度反应停处理后第5d ,A549 与A549 VEGFmRNA表达水平存在显著性差异 ,且蛋白表达与其相应mRNA呈显著正相关。结论 :生理剂量反应停显著上调A549 VEGFmRNA表达 ,但大剂量则抑制其表达 ,同时显著下调A549 VEGFmRNA表达 ,呈剂量依赖性 ,VEGF蛋白表达与mRNA表达量一致。 To explore the effects of thalidomide on the expressions of vasc ular growth factors in parental and cisplatin_resistant human lung adenocarcinom a cell line A549 and A549 .Methods:RT_PCR and Immunohistochemistry were used to detect mRNA and protein expression of VEGF in A549 and A549 .Results:From t he 1st to 5 th day after treatment with physiological concentration of thalidomi de(6 mg/L),VEGF mRNA expression levels in A549 were significant higher than that before treatment.VEGF mRNA expression levels in A549 were significant lower. There were significant differences in A549 and A549 among different concentra tion of thalidomide on the 5 th day.The protein expressions were significant coi ncided with the relative VEGF mRNA expression levels in A549 and A549 .Conclus ion:Physiological concentration of thalidomide up_regulated VEGF mRNA expression significantly in A549.But large dose of thalidomide inhibits VEGF expression si gnificantly.Moreover,thalidomide down_regulated VEGF mRNA expression significant ly in A549 .It is dose_independent.The protein expression is significantly coi ncided with the relative VEGF mRNA.
出处 《天津医药》 CAS 北大核心 2002年第10期608-611,共4页 Tianjin Medical Journal
基金 北京市自然科学基金 (项目编号:7992005) 北京科技新星计划(项目编号:148) 国家"九五"课题攻关项目 (项目编号 :969060123)
关键词 反应停 肺肿瘤 沙立度胺 内皮生长因子 腺癌 lung neoplasms thalidomide endothelial growth factor ade nocarcinoma
  • 相关文献

参考文献11

  • 1[1]Slodkowska J, Sikora J, Roszkowski-Sliz K, et al. Expression of vascular endothelial growth factor and basic fibroblast growth factor receptors in lung cancer. Anal Quant Cytol Histol, 2000, 22: 398~402.
  • 2[2]Kebel RS. Tumor angiogenesis: past, present and the near fu ture. Carcinogenesis, 2000, 21(3): 505~15.
  • 3[3]D' Amato RJ, Loughman MS, Flynn E.Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA, 1994, 91: 4082~5.
  • 4[4]Folkman J.Tumor angiogenesis: Therapeutic implications. N Engl J Med, 1971, 285: 1182~6.
  • 5[5]Minchinton AI, Fryer KH, Wendt KR, et al. The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs, 1996, 7: 339~43.
  • 6[6]Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and tis analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 2000, 96: 2943~ 50.
  • 7[7]Rajkumar SV, Fonseca R, Dispenzieri A, et al. Thalidomide in the treatment of relapsed multiple mye1oma. Mayo Clin Proc, 2000, 89: 488~ 99.
  • 8[8]Singhal S, Mehta J, Desikan R, et al.Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med, 2000, 342: 344.
  • 9[9]Shimazawa R, Miyachi H, Takayama H, et al.Antiangiogenic activity of tumor necrosis factor-α production regulators derived from thalidomide. Biol Phar Bull, 1999, 22(2) :224~6.
  • 10[10]Fine HA, Figg WD, Jaeckle K, et al. Phase trial of the an tiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol, 2000, 18: 708~15.

同被引文献27

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部